Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in Advanced Pancreatic Cancer
NCT00499486Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2005
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in Pancreatic ductal adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Percentage of Patients With Overall Survival at 6 Months, Response Rate (Complete, Partial Response and Stable Disease) at 6 months and 1 more. Started Jan 2005; status: completed.
02
Drugs
sirolimus
03
Conditions
Pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00499486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00499486.